Rapport Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
RAPP$25.96-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
Condensed Consolidated Statement of Equity
(In thousands, except share data)
| For the three months ended March 31, 2026 and 2025 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Stockholders’ Equity | |
| Balance at December 31, 2025 | 47,772,567 | $48 | $719,287 | $546 | $(235,228) | $484,653 |
| Stock-based compensation expense | - | — | 6,963 | — | — | 6,963 |
| Issuance of common stock upon exercise of stock options | 80,867 | — | 809 | — | — | 809 |
| Vesting of restricted stock units | 6,994 | — | — | — | — | — |
| Repurchase of unvested restricted common stock | (52,975) | — | (5) | — | — | (5) |
| Net loss | — | — | — | — | (19,857) | (19,857) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | (1,051) | — | (1,051) |
| Balance at March 31, 2026 | 47,807,453 | $48 | $727,054 | $(505) | $(255,085) | $471,512 |
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · Total | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Stockholders’ Equity | |
| Balance at December 31, 2024 | 36,580,202 | $37 | $429,657 | $(522) | $(123,745) | $305,427 |
| Stock-based compensation expense | — | — | 4,040 | — | — | 4,040 |
| Issuance of common stock upon exercise of stock options | 3,240 | — | 6 | — | — | 6 |
| Repurchase of unvested restricted common stock | (86,008) | — | (1) | — | — | (1) |
| Net loss | — | — | — | — | (24,063) | (24,063) |
| Change in unrealized gain (loss) on investments, net of tax | — | — | — | 427 | — | 427 |
| Balance at March 31, 2025 | 36,497,434 | $37 | $433,702 | $(95) | $(147,808) | $285,836 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.